This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Voxelotor for Sickle Cell Disease

< Back

Voxelotor for Sickle Cell Disease


Haematology and Blood Products

December 2017

Voxelotor is as an oral, once-daily therapy that is being developed for treatment of SCD. It is designed to work by helping haemoglobin hold onto more oxygen as the red blood cells travel through the body. This keeps red blood cells in their normal shape and helps stop sickling. As there is a desperate need for new treatments for SCD, voxelotor, if licensed, will offer a new treatment option for patients with SCD.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Voxelotor for Sickle Cell Disease


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts